Hear from us

ORPHELIA Pharma to collaborate with Oscar Lambret clinical center to study KIZFIZO®, the first pediatric drinkable formulation of temozolomide, for the treatment of refractory or relapsed nephroblastoma (Wilms tumor)

ORPHELIA Pharma and University of Birmingham strengthen their collaboration to support the registration of KIZFIZO®

Orphelia Pharma secures European patent covering KIGABEQ®, the first pediatric formulation of vigabatrin

International Drug Repurposing Conference 2024, 6-7th March 2024, Barcelona

15 February 2024

ORPHELIA Pharma raises awareness for childhood cancer

ORPHELIA Pharma announces the publication of two scientific articles on KIZFIZO, the first pediatric drinkable formulation of temozolomide for the treatment of refractory or relapsed neuroblastoma